Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thermo Fisher, Cellectis Enter TAL Nucleases Licensing Agreement

Published: Thursday, June 05, 2014
Last Updated: Thursday, June 05, 2014
Bookmark and Share
Cellectis and Thermo Fisher Scientific announced that they have entered into a series of agreements covering the uses of TAL nucleases under the brand name TALEN™.

Pursuant to these agreements, Thermo Fisher is granted a worldwide license under Cellectis’ rights to the TAL nucleases outside the therapeutic field, with exclusive rights to grant sublicenses in research and development, bioproduction and certain applied markets. Thermo Fisher currently markets TALEN™ for these applications under its Life Technologies brand. 

Cellectis is granted a worldwide license under Thermo Fisher’s rights to TAL nucleases in the research and development field for internal and collaborative research, for commercialization of TAL gene editing for Cellectis bioresearch’s products and services, and in the plant biotechnology field for Cellectis plant sciences’ in-house and collaborative research and development. Finally, Cellectis is granted a worldwide license for therapeutic research and development, including rights to grant sublicenses for therapeutic uses in the fields of T cells and Natural Killer cells. 

Dr. André Choulika, Chairman and Chief Executive Officer of Cellectis stated: “We are very pleased to enter into these agreements that strengthen Cellectis’ position in the uses of TALEN™ gene editing in Cellectis’ core businesses, and solidifies our position as a leader in the field of engineered CART Chimeric Antigen Receptors therapeutics. TALEN™ is the state-ofthe- art for gene editing and provides exceptional precision, safety, efficacy and ease of use. TAL nucleases have many applications in genome engineering and their efficacy and specificity make them the world’s best gene editing technology for therapeutic applications. Cellectis founded the field of gene editing 14 years ago and is now primarily focused on adoptive immunotherapy using TALEN™-engineered T cells combined with (CARs).” 

“The agreements between Thermo Fisher and Cellectis create a powerful intellectual property portfolio comprised not only of the foundational work conducted at the University of Minnesota and Martin-Luther-Universitat Halle-Wittenberg, but also additional intellectual property controlled by each party,” said Helge Bastian, general manager and vice president of synthetic biology at Thermo Fisher Scientific. “The ability of TAL effectors to bind to DNA with unprecedented precision and reliability makes this technology invaluable to researchers looking to edit genomes and control gene activity. The current alliance clarifies the path for the use of TALEN™ gene editing in research and applied markets, and represents a major milestone in Thermo Fisher’s strategy to build a comprehensive gene editing technology platform.” 

Commercial terms of the agreements were not disclosed. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Transcriptome Profiling Grants Launched
Request for proposal aims to identify promising research projects involving precious samples.
Monday, October 20, 2014
Thermo Fisher Scientific, GSK and Pfizer Collaboration
Thermo Fisher Scientific announces agreement with GlaxoSmithKline and Pfizer to develop oncology companion diagnostics using Next-Generation Sequencing (NGS.)
Thursday, September 25, 2014
Thermo Fisher Scientific and Newman-Lakka Institute to Collaborate
The collaboration will research diagnostic approaches for personalized cancer treatment.
Tuesday, June 25, 2013
Scientific News
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
NCI Collaborates with Multiple Myeloma Research Foundation
NCI collaborates with MMRF to incorporate genomic and clinical data into NCI Genomic Data Commons database.
Regulatory RNA Essential to DNA Damage Response
Researchers discover a tumour suppressor is stabilized by an RNA molecule, which helps cells respond to DNA damage.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Death-or-Repair Switch Protein Identified
Researchers have identified a protein that plays a key role in the decision process of cell damage repair or cellular suicide.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
“Sixth Sense” More Than a Feeling
NIH study of rare genetic disorder reveals importance of touch and body awareness.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!